Back to results
US 2026/0098102 A1Published application
ANTI-SIRPalpha ANTIBODY
AssigneesNational University Corporation Kobe University, Daiichi Sankyo Company, Limited
InventorsTakashi MATOZAKI, Mayumi SUE, Kensuke NAKAMURA, Chigusa YOSHIMURA
Life of this patent
Estimating the term…
Abstract
An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47.
Claims19
An antibody which comprises
- (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO:
- 1;
- (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO:
- 2;
- (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO:
- 3;
- (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO:
- 4;
- (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO:
- 5;
- and
- (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO:
- 6, and
- which is any of the following (1) to (8):
- (1) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 41;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 37;
- (2) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 41;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with amino acid residues 21 to 127 in SEQ ID NO:
- 37;
- (3) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 41;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 39;
- (4) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 41;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 39;
- (5) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 43;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 35;
- (6) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 43;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 35;
- (7) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 43;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 37;
- and
- (8) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of:
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO:
- 43;
- and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO:
- 37.
52 more elements
Dependencies are inferred from the claim text.